Reuters logo
BRIEF-Celgene Reports Long-Term Efficacy Data From Phase III Geparsepto Study
December 7, 2017 / 6:12 PM / in 6 days

BRIEF-Celgene Reports Long-Term Efficacy Data From Phase III Geparsepto Study

Dec 7 (Reuters) - Celgene Corp:

* LONG-TERM EFFICACY DATA FROM THE PHASE III GEPARSEPTO STUDY IN HIGH RISK EARLY BREAST CANCER PATIENTS TREATED WITH ABRAXANE VS. SOLVENT-BASED PACLITAXEL TO BE REPORTED

* STUDY FOUND SIGNIFICANTLY HIGHER DFS RATE IN PATIENTS GETTING ABRAXANE VERSUS THOSE GETTING PACLITAXEL IN NEOADJUVANT REGIMEN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below